(0.89%) 5 109.05 points
(0.91%) 38 575 points
(1.65%) 16 103 points
(-0.65%) $78.44
(4.03%) $2.12
(-0.42%) $2 300.00
(-0.92%) $26.58
(-0.04%) $962.20
(-0.42%) $0.928
(-1.28%) $10.85
(-0.13%) $0.797
(0.31%) $91.41
Live Chart Being Loaded With Signals
Promore Pharma AB (publ), a biopharmaceutical company, develops peptide-based drug candidates in Sweden and internationally. Its product candidates include PXL01 that is in Phase IIa study for the prevention of post-surgical adhesions and scars, and for the prevention of dermal scars, as well as for tendon repair surgery in the hand; and LL-37, which is in Phase IIb clinical studies for treating patients with venous leg ulcers, stimulate the healing of chronic wounds, and for the treatment of diabetic foot ulcers...
Stats | |
---|---|
本日の出来高 | 1.12M |
平均出来高 | 2.06M |
時価総額 | 293.55M |
EPS | SEK-0.0643 ( 2023-09-30 ) |
Last Dividend | SEK0 ( N/A ) |
Next Dividend | SEK0 ( N/A ) |
P/E | -0.314 |
ATR14 | SEK5.16 (36.49%) |
ボリューム 相関
Promore Pharma AB (publ) 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Promore Pharma AB (publ) 相関 - 通貨/商品
Promore Pharma AB (publ) 財務諸表
Annual | 2022 |
収益: | SEK99 000.00 |
総利益: | SEK-15.85M (-16 005.05 %) |
EPS: | SEK-0.440 |
FY | 2022 |
収益: | SEK99 000.00 |
総利益: | SEK-15.85M (-16 005.05 %) |
EPS: | SEK-0.440 |
FY | 2021 |
収益: | SEK417 000 |
総利益: | SEK-14.90M (-3 571.94 %) |
EPS: | SEK-0.561 |
FY | 2020 |
収益: | SEK3 000.00 |
総利益: | SEK-18.20M (-606 733.33 %) |
EPS: | SEK-0.796 |
Financial Reports:
No articles found.
Promore Pharma AB (publ)
Promore Pharma AB (publ), a biopharmaceutical company, develops peptide-based drug candidates in Sweden and internationally. Its product candidates include PXL01 that is in Phase IIa study for the prevention of post-surgical adhesions and scars, and for the prevention of dermal scars, as well as for tendon repair surgery in the hand; and LL-37, which is in Phase IIb clinical studies for treating patients with venous leg ulcers, stimulate the healing of chronic wounds, and for the treatment of diabetic foot ulcers. It entered into a cooperation agreement with Fidia Farmaceutici S.p.A. for the production of hyaluronic acid syringes. The company was formerly known as Lipopeptide AB and changed its name to Promore Pharma AB (publ) in January 2017. Promore Pharma AB (publ) was founded in 2002 and is headquartered in Solna, Sweden.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。